Rapid & accurate results direct from blood culture The bioMérieux comprehensive Sepsis Solution, with the addition VITEK ® REVEAL™, helps to manage your patient therapy all along the pathway bringing you rapid and reliable results to support clinical decisions for better patient care. Hourly delays in antibiotic administration were associated with increased odds of hospital mortality even among patients who received antibiotics within 6 hours. Predicting antimicrobial resistance (AMR), can be more complex and time-intensive for patients with Gram negative infections.Įarly diagnosis and appropriate treatment make a critical difference when it comes to improving sepsis patient outcomes. Keeping testing in-house may streamline the diagnostic workflow and get answers to patients during their clinic visit, which is why the SPOTFIRE System is designed specifically to be used by non-laboratory professionals.VITEK ® REVEAL™: THE NEW ADDITION TO THE BIOMÉRIEUX SEPSIS SOLUTION Sepsis management The targeted SPOTFIRE R Panel Mini, developed alongside the SPOTFIRE R Panel, tests for 5 viral targets in the same time frame, bringing new possibilities and options to clinicians.Īnother game-changing element is the user-friendly nature of the SPOTFIRE System interface. One PCR test of 15 targets-including 11 viruses and four bacteria-can produce results in about 15 minutes. And with that the expanded SPOTFIRE R Panel was born. We also optimized the chemistry to run faster and perform better. In that vein, we tailored the SPOTFIRE System’s panel menus to include the most common pathogens that cause respiratory tract infections. However, the BIOFIRE RP2.1 Panel was created for a laboratory setting, and we needed to bring that same quality of testing to the CLIA-waived market. The associated risk with COVID-19 made differential respiratory diagnoses increasingly important, as they helped clinicians determine the appropriate quarantine and treatment measures. With a target menu of 22 probable pathogens, including SARS-CoV-2, the BIOFIRE R2.1 Panel was a game changer during the pandemic. And given that the pandemic highlighted the need for better POC respiratory testing, we turned to the BIOFIRE ® Respiratory 2.1 (RP2.1) Panel. Delivering syndromic results in a clinically relevant time frameįrom the onset, we knew we had to bring the syndromic approach to point-of-care settings.Bringing PCR-based testing to the point of care.Making an instrument easy enough to use in a CLIA-waived setting.When developing the SPOTFIRE Respiratory Solution, bioMérieux had three things in mind: Fast forward to 2023 and we have launched the SPOTFIRE SYSTEM, along with the BIOFIRE ® SPOTFIRE ® Respiratory Panel and the BIOFIRE ® SPOTFIRE ® Respiratory Panel Mini, with FDA clearance and a CLIA waiver. This can have negative impacts on patient management and antimicrobial stewardship.īioMérieux recognized this critical gap in patient care and began developing the BIOFIRE ® SPOTFIRE ® System in 2016.

However, some clinics don’t have the resources to perform lab-grade testing onsite, which often leaves providers to make diagnoses and prescribe treatment based solely on clinical signs and symptoms. Patients visit urgent care and other POC centers because of their streamlined and convenient process-they come wanting fast answers and relief. This scenario is unfortunately not uncommon in point-of-care (POC) settings. The doctor must now get back to the mother and inform her that the antibiotics will not be effective and that the best therapy is to manage symptoms and monitor for signs of more severe illness. The doctor prescribes broad-spectrum antibiotics in the hopes they will relieve the symptoms.īut it’s not until after the mother fills the prescription and begins administering the antibiotics that the doctor gets back the results: the boy has a viral infection caused by respiratory syncytial virus (RSV), a key player in the 2022/23 “tripledemic” (the simultaneous circulation of influenza, COVID-19, and RSV during the respiratory season). Wanting to give her child relief immediately, the mother asks the doctor for treatment options. Understandably concerned, the mother demands an answer, so the doctor takes another swab that would test for additional pathogens however, the results will take time to come in. The doctor tests for COVID-19, but the result comes back negative. The boy presents with respiratory symptoms-cough, runny nose, fever-and the mother is concerned it may be COVID-19. A mother comes into an urgent care facility with her 5-year-old son.

Biofire diagnostics